Stereotaxis and inHEART Combine Robotic Precision and Advanced Preoperative 3D Mapping to Treat Cardiac Arrhythmias
November 05 2019 - 9:00AM
Stereotaxis (NYSE American: STXS) and inHEART today announced the
first patients have been successfully treated with the integration
of inHEART’s advanced preoperative mapping and Stereotaxis’ Robotic
Magnetic Navigation technologies.
inHEART applies advanced algorithms on
preoperative CT and MRI images to generate highly detailed
three-dimensional maps of the heart. These maps display key
structural information on the cardiac chambers, epicardium,
coronary vasculature, phrenic nerves, and arrhythmogenic substrate.
This information aids physicians in diagnosing the source of
irregular heartbeats and planning cardiac ablation procedures. The
latest version of Stereotaxis software, recently cleared for use in
Europe and by the FDA, utilizes a software interface that
integrates inHEART’s maps, cleared for use in Europe, and allows
physicians to utilize them to guide robotic cardiac ablation
procedures. The first integrated procedures were successfully
conducted by Dr. Riho Luite of Kuopio University Hospital in
Kuopio, Finland.
“Understanding the unique structural
characteristics of each patient’s heart is valuable in designing
optimal individualized therapy,” said Dr. Riho Luite. “The next
challenge arises in delivering therapy to the appropriate areas of
interest, particularly in hearts that have unusual anatomies or in
chambers that have complex internal structures. The unmatched
catheter reach and precision provided by Stereotaxis robotic
technology combined with the roadmap provided by inHEART simplifies
procedures and helps provide the best possible care for
patients.”
“We are really excited about this successful
combination of inHEART’s high resolution mapping with Stereotaxis’
robotic precision,” said Dr. Jean-Marc Peyrat, inHEART CEO. “This
is a first step towards leveraging the full potential of combining
both technologies to ease and standardize these complex
interventions, and eventually to make effective cardiac catheter
ablation accessible to most patients.”
“Stereotaxis is committed to advancing a robust
open ecosystem where physicians and patients benefit from the broad
integration of procedure data,” said David Fischel, CEO of
Stereotaxis. “We are excited to be working with inHEART. Increased
use of advanced preoperative imaging supports personalized
patient-specific therapy, and in combination with robotics is a
step forward in the digitization of interventional medicine.”
About inHEARTinHEART is a
leader in image-based preoperative 3D mapping for cardiac ablation
procedures. inHEART’s vision is to bridge the gap between medical
imaging and cardiac electrophysiology to advance the treatment of
cardiac arrhythmias to the next level with simpler, faster, and
more standardized ablation procedures. inHEART has recently
received regulatory clearance in Europe. For more information,
please visit www.inheart.fr.
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. Stereotaxis’ robotic technology has
received various regulatory clearances in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to raise additional capital on a
timely basis and on terms that are acceptable, its ability to
continue to manage expenses and cash burn rate at sustainable
levels, its ability to continue to work with lenders to extend,
repay or refinance indebtedness, or to obtain additional financing,
in either case on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Stereotaxis: |
inHEART: |
David Fischel |
Jean-Marc Peyrat, PhD, MBA |
Chairman and CEO |
CEO |
|
|
Kimberly Peery |
+33 5 35 38 19 72 |
CFO |
contact@inheart.fr |
|
|
314-678-6100 |
|
investors@stereotaxis.com |
|
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024